Lv11
40 积分 2024-06-22 加入
Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer
2小时前
待确认
Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR-mutated non-small cell lung cancer
22天前
已完结
EP.11.21 Efficacy of Immunotherapy in EGFR-Mutant NSCLC After Tyrosine Kinase Inhibitors: Real World Analysis at a Tertiary Oncology Center in Hong Kong
29天前
已关闭
EGFR‐targeted therapy alters the tumor microenvironment in EGFR‐driven lung tumors: Implications for combination therapies
1个月前
已完结
Tumor‐associated macrophages correlate with response to epidermal growth factor receptor‐tyrosine kinase inhibitors in advanced non‐small cell lung cancer
1个月前
已完结
Targeting KRAS in cancer
1个月前
已完结
A single inhibitor for all KRAS mutations
1个月前
已完结
P3.12.73 Phase I/II Study on WSD0922-FU in EGFR C797S+ NSCLC
1个月前
已完结
A Comprehensive Review of Marketed KRAS Inhibitors and Degraders: Challenges and Opportunities
1个月前
已完结
An overview of KRAS G12D inhibitors: Expanding the therapeutic frontier of KRAS in targeting KRAS G12D using diverse therapeutic modalities
2个月前
已完结
皖公网安备34019202002308
